Biotechnology
Biogen Could Rally in the Weeks Ahead
Buyers have returned in recent months and the stock could be ready to rise.
AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
Acer Plummets After FDA Declines to OK Rare Genetic Disorder Treatment
Acer plummets toward a record low after the Food and Drug Administration declined to approve its treatment for a genetic disorder that can cause blood vessels to fatally rupture.
Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
AbbVie Fizzles, Gold, Bitcoin and (Some) Biotech Sizzles
AbbVie is dropping on Allergan deal announcement, momentum is weak outside certain pockets.
A Handful of Small Biotechs That Make for Merger Chatter
The names include a veterinary drug concern plus companies with successful drugs on the market.
Jitters Not Justified
Despite steady selling Thursday the markets are not on the verge of disaster -- and thanks to several IPOs, opportunities are here.
2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land
These two firms have successful drugs and could make nice additions for larger companies.